Search

Displaying results 2411 - 2420 of 10000 in total
  1. Drug

    Aceclidine

    go.drugbank.com/drugs/DB13262
    Approved

    Aceclidine is a cholinergic muscarinic agonist which began marketing in Europe in the 1970s for the treatment of glaucoma. … [A274278] Aceclidine was approved the US FDA in July 2025 for the treatment of adult patients with presbyopia.[L53768]

  2. Drug

    Seladelpar

    go.drugbank.com/drugs/DB12390
    ApprovedInvestigational

    [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism

  3. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. … It was rejected for approval for use in the United States.

  4. Drug

    Sevoflurane

    go.drugbank.com/drugs/DB01236
    ApprovedInvestigationalVet approved

    [L42340] Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. … Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia.

  5. Drug

    LetibotulinumtoxinA

    go.drugbank.com/drugs/DB16820
    Approved

    [L42335] It was approved for use in the treatment of glabellar lines in Canada in June 2022[L42330,L42335] and in the US in March 2024.[L50291,L50296] … The aesthetic utility of botulinum toxin was discovered incidentally following its initial use in the treatment of facial spasmodic disorders in the early 1970s.

  6. Drug

    Palopegteriparatide

    go.drugbank.com/drugs/DB18676
    ApprovedInvestigational

    [L51134] PTH(1-34) contains the N-terminal part of the endogenous PTH molecule. … [L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA.

    Synonyms: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34, Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-L-seryl-L-valyl-L-seryl-L-α-glutamyl-L-isole
  7. Drug

    Sibeprenlimab

    go.drugbank.com/drugs/DB18919
    ApprovedInvestigational

    [L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628] … [A274848, A274853, A274858] Elevated APRIL levels are often observed in inflammatory disorders, including immunoglobulin A nephropathy (IgAN).

  8. Drug

    Mecobalamin

    go.drugbank.com/drugs/DB03614
    ApprovedInvestigational

    Mixtures: EnLyte Extra-LNProducts: N-cobal 0.5mg film-coated tablet
  9. Drug

    Gadoquatrane

    go.drugbank.com/drugs/DB33282
    Approved

    in the central nervous system and in the body. … [L63930] Bayer announced FDA approval of gadoquatrane on June 15, 2026, for use with MRI in adult and pediatric patients, including term neonates, to detect and visualize lesions with abnormal vascularity

  10. Drug

    Calcium threonate

    go.drugbank.com/drugs/DB11168
    ApprovedWithdrawn

    L-threonate is an active metabolite of vitamin C that mediates a stimulatory action on vitamin C uptake [A27266]. … Therapeutic efficacy of calcium threonate in reducing was studied and investigated due to the hypothesis that it may play a role in the mineralization process through its positive action on vitamin C.